Moderna 2022 Priorities and Capital Allocation
Moderna's respiratory vaccines: Flu vaccine (mRNA-1010)
expected to start Phase 3 in 2Q22
Pipeline Highlights
COVID-19 variant boosters and next generation
mRNA-1283 in development
Flu (mRNA-1010) Phase 2 positive data
announced in March; expected to start Phase 3
safety & immunogenicity trial in 2Q22 to support
potential accelerated approval and preparing for
Phase 3 efficacy study in Fall 2022 (if needed);
Flu (mRNA-1020/-30) started Phase 1/2 trial in April
Older adults RSV Phase 3, known as ConquerRSV,
is ongoing; Pediatric RSV in Phase 1
Combination COVID + flu (mRNA-1073) and
combination COVID + flu + RSV (mRNA-1230) in
preclinical, expected to start Phase 1 trials in 2022;
Endemic HCoV in preclinical
Pediatric hMPV + PIV3 Phase 1b fully enrolled;
Pediatric RSV + hMPV in preclinical
Adults
Preclinical
development
Delta variant
Beta variant + wild-type
Beta Delta variant
Modality
Program
ID #
Phase 1
Phase 2
Phase 3
Commercial
Moderna rights
mRNA-1273/Spikevax®
Worldwide
mRNA-1273.351
mRNA-1273.617
mRNA-1273.211
Beta variant
Worldwide
Worldwide
Worldwide
COMID-19 vaccine
mRNA-1273.213
mRNA-1273.529
mRNA-1273.214
Worldwide
mRNA-1283
Omicron variant
Omicron variant + wild-type
Next generation (2-5 °C)
Worldwide
Worldwide
Worldwide
mRNA-1010
Phase 3 prep
Worldwide
mRNA-1011
Worldwide
mRNA-1012
Worldwide
mRNA-1020
Worldwide
mRNA-1030
Worldwide
Older adults RSV vaccine
COVID + Flu vaccine
mRNA-1345
Worldwide
mRNA-1073
Worldwide
COVID + Fu+ RSV vaccine
Endemic HCOV vaccine
mRNA-12:30
Worldwide
mRNA-1287
Worldwide
COVID-19 vaccine (adolescents)
mRNA-1273
Teen COVE
Worldwide
mRNA-1273
Worldwide
mRNA-1345
Worldwide
Pediatric hMPV + PIV3 vaccine
Pediatric RSV + hMPV vaccine
mRNA-1653
Worldwide
mRNA-1365
Worldwide
Flu vaccine
Adolescents COVID-19 vaccine (pediatrics)
Pediatric RSV vaccine
& Pediatrics
KidCOVE
Slide 23
modernaView entire presentation